Ataxin 1 Antikörper

Produktnummer ABIN968970

Produktdetails anti-Ataxin 1 Antikörper

Target: Ataxin 1 (ATXN1)

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Ataxin 1 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC), ELISA, Immunocytochemistry (ICC), Flow Cytometry (FACS)

Verwendungszweck: ATXN1 Antibody

Aufreinigung: Ascitic fluid

Immunogen: Purified recombinant fragment of human ATXN1 expressed in E. Coli.

Klon: 2F5

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise:

ELISA: 1/10000

FCM: 1/200 - 1/400

ICC: 1/200 - 1/1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Referenzen für anti-Ataxin 1 Antikörper (ABIN968970)

Lim, Crespo-Barreto, Jafar-Nejad, Bowman, Richman, Hill, Orr, Zoghbi: "Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1." in: Nature, Vol. 452, Issue 7188, pp. 713-8, (2008) (PubMed).

Details zu Ataxin 1

Target: Ataxin 1 (ATXN1)

Andere Bezeichnung: ATXN1 (ATXN1 Produkte)

Synonyme: ATX1 antikoerper, D6S504E antikoerper, SCA1 antikoerper, ATXN1 antikoerper, ataxin 1b antikoerper, atxn1 antikoerper, 2900016G23Rik antikoerper, Atx1 antikoerper, C85907 antikoerper, ENSMUSG00000074917 antikoerper, Gm10786 antikoerper, Sca1 antikoerper, CG4547 antikoerper, Dmel\\CG4547 antikoerper, dAtx-1 antikoerper, dAtx1 antikoerper, sca1 antikoerper, ataxin 1 antikoerper, ataxin 1b antikoerper, Ataxin 1 antikoerper, ATXN1 antikoerper, atxn1b antikoerper, Atxn1 antikoerper, Atx-1 antikoerper

Hintergrund:

Description: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 41-81 CAG repeats, compared to 6-39 in the normal allele. At least two transcript variants encoding the same protein have been found for this gene.Tissue specificity: Widely expressed throughout the body.

Aliases: ATX1, SCA1, D6S504E, ATXN1

Molekulargewicht: 87kDa

Gen-ID: 6310

HGNC: 6310

UniProt: P54253

Pathways: Synaptic Membrane